[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].

Abstract

Treatment of type 2 diabetes (T2DM) is based on lifestyle changes and oral antidiabetic agents or insulin. The UKPDS study has confirmed metformin (Met) as the initial monotherapy. Accordingly, Met is widely regarded as the first drug of choice for most patients with T2DM. Safety and efficacy of sulphonylureas (SU) have been confirmed by several clinical… (More)
DOI: 10.1016/j.revmed.2008.05.011

Topics

  • Presentations referencing similar topics